Kiniksa Pharmaceuticals, Ltd. - (KNSA): Price and Financial Metrics
Kiniksa Pharmaceuticals, Ltd. - (KNSA)
Today's Latest Price: $19.19 USD
Updated Jan 28 11:15am
Add KNSA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 241 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
KNSA Stock Price Chart Interactive Chart >
KNSA Price/Volume Stats
| Current price | $19.19 | 52-week high | $28.67 |
| Prev. close | $19.44 | 52-week low | $10.30 |
| Day low | $19.01 | Volume | 41,515 |
| Day high | $20.00 | Avg. volume | 284,588 |
| 50-day MA | $18.17 | Dividend yield | N/A |
| 200-day MA | $19.13 | Market Cap | 1.31B |
Kiniksa Pharmaceuticals, Ltd. - (KNSA) Company Bio
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda
Loading social stream, please wait...